IMI to Boost Patient Involvement in its Activities

Innovative Medicines InitiativeThe Innovative Medicines Initiative (IMI) is creating a 'pool' of patient experts to strengthen the role and voice of patients in IMI activities at both strategic and operational levels. IMI has always involved patients in its work; now the plan is to take patient engagement at IMI to the next level.

IMI has involved patients in its projects and activities since the very beginning - as project partners, as members of the IMI Scientific Committee, and as speakers in our events, for example. Now, IMI wants to enhance the involvement of patients in all activities, for example by inviting them to provide input on scientific strategies; review project proposals; and assess the results of ongoing and closed projects.

To facilitate this, IMI is establishing a pool of patient experts that is open to a wide range of patients (and family members and carers) with a chronic illness or condition that is linked to IMI’s Strategic Research Agenda. The conditions for being part of the pool are simple and people who are interested in getting involved can submit an expression of interest via the IMI website.

When registering their interest, patients will be asked about their knowledge and experience of medical research and drug development, among other things. Whenever IMI has a task or activity that would benefit from patient input, the IMI Programme Office will turn to the pool to find the patient(s) with the most relevant knowledge and experience. For all tasks, patients will act in their personal capacity.

IMI Executive Director Dr Pierre Meulien said: "Patient engagement has always been a priority for IMI, and I am convinced that patients can and should be actively involved as equal partners in medical research and innovation. I hope that this pool of patient experts will provide both patients with a channel to influence research into their disease or condition, and IMI with information that will allow us to deliver projects that are truly aligned with patients’ needs."

Benefits for patients of getting involved in this new initiative include the opportunity to influence IMI’s activities on both strategic and operational levels; work alongside experts from other sectors (academia, industry, regulatory, etc.); raise the profile of patients as equal partners in research in the IMI community and beyond; and learn first-hand about the latest research developments in their disease area.

More information on the criteria for inclusion in the pool, how to apply, and the kinds of tasks participants could expect to be involved in, can be found in via this web page.

Deadline for submitting expressions of interest: 16 July 2019 at 17:00 CEST (Central European Summer Time / Brussels time)

IMI will hold a webinar for people interested in joining the pool on Tuesday 18 June at 14:00 CEST. Registration is free but obligatory via this link.

About the Innovative Medicines Initiative

The Innovative Medicines Initiative (IMI) is working to improve health by speeding up the development of, and patient access to, the next generation of medicines, particularly in areas where there is an unmet medical or social need. It does this by facilitating collaboration between the key players involved in healthcare research, including universities, pharmaceutical companies, other companies active in healthcare research, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. This approach has proven highly successful, and IMI projects are delivering exciting results that are helping to advance the development of urgently-needed new treatments in diverse areas.

IMI is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). Through the IMI2 programme, IMI has a budget of €3.3 billion for the period 2014-2020. Half of this comes from the EU’s research and innovation programme, Horizon 2020. The other half comes from large companies, mostly from the pharmaceutical sector; these do not receive any EU funding, but contribute to the projects 'in kind', for example by donating their researchers' time or providing access to research facilities or resources.

Most Popular Now

People may Trust Computers more than Hum…

Despite increasing concern over the intrusion of algorithms in daily life, people may be more willing to trust a computer program than their fellow humans, especially if a task becomes...

Alcidion Acquires UK Patient Flow Softwa…

Smart health technology provider Alcidion Group has today announced the strategic acquisition of ExtraMed, a UK company which specialises in providing NHS trusts with software that helps frontline staff make...

Microsoft Accelerates Industry Cloud Str…

Microsoft Corp (Nasdaq: MSFT) and Nuance Communications, Inc. (Nasdaq: NUAN) have entered into a definitive agreement under which Microsoft will acquire Nuance for $56.00 per share, implying a 23% premium...

Expediting the Diagnosis of Heart Attack…

Siemens Healthineers announced today the company's Atellica VTLi Patient-Side Immunoassay Analyzer(1) has obtained CE mark and is expected to be available later this spring. The Atellica VTLi analyzer provides lab...

New AI Tool Tracks Evolution of COVID-19…

A new machine-learning program accurately identifies COVID-19-related conspiracy theories on social media and models how they evolved over time - a tool that could someday help public health officials combat...

Siemens Healthineers Completes Acquisiti…

Siemens Healthineers AG (Frankfurt: SHL) announced that it has successfully completed the acquisition of Varian Medical Systems, Inc. ("Varian"). The acquisition was previously announced on August 2, 2020. "With Varian, Siemens...

Talking Health Tech

Opinion Article by Andy Kinnear, Partnerships Director, Ethical Healthcare Consulting. Ethical is different. The guy who founded it, [chief executive] Thomas Webb, comes from an NHS background and he is very...

Commission Opens First European Innovati…

Following the launch of the European Innovation Council (EIC) and the announcement of the first funding opportunities, today the Commission opened the first EIC Accelerator calls. The funding worth over...

Artificial Intelligence Model Predicts w…

The human immune defense is based on the ability of white blood cells to accurately identify disease-causing pathogens and to initiate a defense reaction against them. The immune defense is...

Call for Papers: DigiHealthDay-2021

12 November 2021 The DigiHealthDay 2021 is an International Symposium with the theme "Global Digital Health - Today, Tomorrow, and Beyond". The abstracts pertaining to the field of digital health and...

International Master in Digital Health i…

The Master of Digital Health, MDH (formerly - Master of Medical Informatics, MMI) at European Campus Rottal-Inn (ECRI) - a branch of the Deggendorf University of Applied Sciences (DIT) in Bavaria...

Proposal for a Regulation Laying Down Ha…

Artificial Intelligence (AI) is a fast evolving family of technologies that can bring a wide array of economic and societal benefits across the entire spectrum of industries and social activities...